PMB’s focus is on launching clinical trials for GBM and DIPG using its product, Immune¹², a complex biologic compound derived from marine organisms.

• GBM and DIPG are orphan diseases with no cure. Current treatments may extend life by several months but are not curative.
• Upon diagnosis, patients face a grim reality with little to no hope for recovery. While existing standard-of-care treatments like radiation and chemotherapy may extend life by a few months, they fall significantly short of providing a cure. Moreover, the side effects associated with these treatments can be severe and debilitating, further compromising the quality of life for patients.